bluebird bio, Inc. Receives FDA Lifting of Partial Clinical Hold for Lovotibeglogene Autotemcel

bluebird bio, Inc. announced that the U.S. Food and Drug Administration lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel (lovo-cel) for sickle cell disease on December 19, 2022. This decision comes after an investigation into a case of persistent, non-transfusion-dependent anemia following treatment with lovo-cel in an adolescent patient, as well as an adult patient with a similar condition. The hold was initially placed in December 2021, and patients with a specific genotype known as an alpha-thalassemia trait were added to the exclusion criteria for ongoing studies.

Key Takeaways:

• The U.S. FDA lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel (lovo-cel) for sickle cell disease on December 19, 2022.
• The hold was initially placed in December 2021 due to an investigation into a case of persistent, non-transfusion-dependent anemia following treatment with lovo-cel in an adolescent patient.
• Patients with a specific genotype known as an alpha-thalassemia trait were added to the exclusion criteria for ongoing studies.
• The lifting of the partial clinical hold is significant for bluebird bio, Inc. as it allows for the continuation of clinical studies for lovo-cel in patients under the age of 18.
• Lovotibeglogene autotemcel is being evaluated as a potential treatment for sickle cell disease, a genetic disorder that affects hemoglobin production.

Statistics:

• The partial clinical hold was lifted on December 19, 2022.
• The hold was initially placed on December 1, 2021.
• Over 1,800 patients have been enrolled in clinical studies for lovo-cel in sickle cell disease.
• Sickle cell disease affects approximately 100,000 people in the United States, with 1 in every 365 African American births affected.

Sources:

• bluebird bio, Inc. (Exact name of Registrant as Specified in Its Charter)
• UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
• Form 8-K with the Securities and Exchange Commission on December 19, 2022.